Stay up to date
recent news & press releases
When it comes to diagnostic technology, the more options a clinician has the better, particularly for cancer. Exai Bio is developing liquid biopsy tests using non-coding RNA or oncRNA technology and AI to give clinicians a way to assess cancer with a simple blood test.
In a recent interview with CLP, Pat Arensdorf, our co-founder and chief executive officer, discussed how the company’s technology uses next generation sequencing (NGS) and AI, where oncRNA technology fits into the existing diagnostic continuum, and the benefits that oncRNA-based tests will contribute compared to other types of liquid biopsy test.